Karley S. Whalen

Karley S. Whalen

Auto-generated profile, based on publicly available information

Karley S. Whalen

Dana-Farber Cancer Institute 1 Department of Medical Oncology Harvard Medical School, Boston, Massachusetts

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2026 in Blood Cancer Discovery
Verified
Journal Article
Open access
QLQingyu Luo
Qingyu Luo
KWKarley S. Whalen
Karley S. Whalen
XWXiaowei Wu
Xiaowei Wu
AFAmanda L. Fortune
Amanda L. Fortune
JGJacqueline S. Garcia
Jacqueline S. Garcia
ALAndrew A Lane
Andrew A Lane
Acute myeloid leukemia (AML) is prone to relapse driven by therapy-persistent residual cells. To discover specific vulnerabilities in this population, we performed genome-wide CRISPR interference screens in leukemia cells treated with multiple agents. KHSRP was the top hit, the depletion of which sensitized AML cells to therapy and substantially prolonged survival in treated AML-bearing mice. Analysis of in vivo residual disease after venetoclax/azacitidine treatment identified downregulation of the vitamin C and uric acid transporter SLC23A1, which mediated resistance to multiple therapies. KHSRP depletion restored SLC23A1 expression by preventing its ZC3H4-mediated nuclear mRNA degradation. KHSRP depletion therefore enhanced the synergistic cytotoxicity of vitamin C and uric acid, particularly in therapy-persistent leukemia cells. Re-expression of TET2 overrode the chemosensitizing effect of KHSRP depletion in TET2-mutant leukemia, suggesting that KHSRP-linked phenotypes were related to vitamin C– and uric acid–mediated TET activation. These findings suggest targeting KHSRP to enhance treatment efficacy and selectively eradicate residual AML. Significance: Residual AML cells that persist following therapy have distinct biological properties compared with initial disease or overt relapse. Here, we nominate KHSRP as a target to improve therapy efficacy and exploit selective vulnerabilities of AML residual disease.

3 November 2026
Verified
Other
Open access
QLQingyu Luo
Qingyu Luo
KWKarley S. Whalen
Karley S. Whalen
XWXiaowei Wu
Xiaowei Wu
AFAmanda L. Fortune
Amanda L. Fortune
JGJacqueline S. Garcia
Jacqueline S. Garcia
ALAndrew A Lane
Andrew A Lane
Sequences of guide RNA and cDNA

3 November 2026
Verified
Other
Open access
PDF file
QLQingyu Luo
Qingyu Luo
KWKarley S. Whalen
Karley S. Whalen
XWXiaowei Wu
Xiaowei Wu
AFAmanda L. Fortune
Amanda L. Fortune
JGJacqueline S. Garcia
Jacqueline S. Garcia
ALAndrew A Lane
Andrew A Lane
Figure S1. KHSRP depletion selectively reduces residual leukemia cell viability. Figure S2. SLC23A1 expression is reduced in residual leukemia populations. Figure S3. KHSRP promotes SLC23A1 mRNA decay via ZC3H4. Figure S4. KHSRP depletion reduces residual leukemia cell persistence after various chemotherapies.

3 November 2026
Verified
Other
Open access
QLQingyu Luo
Qingyu Luo
KWKarley S. Whalen
Karley S. Whalen
XWXiaowei Wu
Xiaowei Wu
AFAmanda L. Fortune
Amanda L. Fortune
JGJacqueline S. Garcia
Jacqueline S. Garcia
ALAndrew A Lane
Andrew A Lane
Fold change of all genes in the CRISPRi screen

3 November 2026
Verified
Other
Open access
QLQingyu Luo
Qingyu Luo
KWKarley S. Whalen
Karley S. Whalen
XWXiaowei Wu
Xiaowei Wu
AFAmanda L. Fortune
Amanda L. Fortune
JGJacqueline S. Garcia
Jacqueline S. Garcia
ALAndrew A Lane
Andrew A Lane
Supplementary Table S1 from Therapy-Persistent Leukemia Is Selectively Vulnerable to SLC23A1 Restoration via Targeting KHSRP

3 November 2026
Verified
Other
Open access
QLQingyu Luo
Qingyu Luo
KWKarley S. Whalen
Karley S. Whalen
XWXiaowei Wu
Xiaowei Wu
AFAmanda L. Fortune
Amanda L. Fortune
JGJacqueline S. Garcia
Jacqueline S. Garcia
ALAndrew A Lane
Andrew A Lane
Genes with differential splicing after KHSRP depletion